Cardiff Oncology (CRDF) Stock Analysis: AI Score & Alternative Data
Demand signals are heating up for Cardiff Oncology
Is Cardiff Oncology a buy right now? The alternative data says hold. This CRDF stock analysis is built on the 25+ alternative data signals AltIndex tracks on Cardiff Oncology every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 57/100: a Hold. The stock trades at $1.21 with a $94M market cap.
The data leans positive over the past 90 days — web traffic up 23.6% to 5K monthly visits — but the move hasn’t been broad enough to lift CRDF into buy territory yet.
CRDF’s broader alt-data profile also covers headcount (51 employees, according to LinkedIn), Facebook followers (1K), Reddit mentions (3 a day), and sentiment (100/100). Every signal links to its own page with full history, the CRDF technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on CRDF is just below.
Cardiff Oncology AI Stock Analysis
Cardiff Oncology is a clinical-stage biotechnology company focused on developing novel cancer treatments. The company's flagship product is Onvansertib, which has shown promise in clinical trials for multiple cancer indications. Based in San Diego, California, Cardiff Oncology is committed to advancing precision medicine approaches in oncology to improve patient outcomes.
Analysis generated September 2, 2026.
Recent Cardiff Oncology Stock Alerts
|
Cardiff Oncology | September 10 Price is up by 6.2% in the last 24h. |
|
Cardiff Oncology | September 1 Price is up by 6.7% in the last 24h. |
|
Cardiff Oncology | August 31 Price is up by 6.1% in the last 24h. |
|
Cardiff Oncology | August 25 Price is up by 6.2% in the last 24h. |
Cardiff Oncology Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 5K | 23.6% | |
| Job Posts | 0 | 100.0% | |
| LinkedIn Employees | 51 | 0% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 3 | N/A | |
| X Mentions | 2 | 100.0% | |
| Stocktwits Mentions | 140 | 27.3% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 19K | 0% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 1K | 0% | |
| Facebook Followers | 1K | 0% | |
| Facebook Engagement | 0 | N/A |
About Cardiff Oncology (CRDF)
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California.
| Price | $1.21 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $94M |
| Year Range | $1 – $3 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Cardiff Oncology News
View more →
Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential?June 30 - Yahoo Entertainment |
|
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual MeetingJune 2 - GlobeNewswire |
|
Cardiff Oncology to Participate in the Jefferies Global Healthcare ConferenceJune 1 - GlobeNewswire |
|
Cardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRCMay 21 - GlobeNewswire |
|
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 28 - GlobeNewswire |
|
See Cardiff Oncology’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for CRDF, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREECardiff Oncology Earnings & Financial Performance
View all earnings →Cardiff Oncology Insider Trading Activity
View all →| Mohindru Mani filed to sell 34,364 shares at $0.0. Jul 14 '26 |
| PACE GARY W filed to sell 687,285 shares at $0.0. Jul 14 '26 |
| PACE GARY W filed to sell 1,356,376 shares at $0.0. Jun 18 '26 |
| Mohindru Mani filed to sell 24,703 shares at $0.0. Jun 18 '26 |
| PACE GARY W filed to sell 1,345,676 shares at $0.0. Jul 30 '25 |
Cardiff Oncology Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Cardiff Oncology
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
NeOnc TechnologiesNTHI |
$3.62 1.1% | $95M | 60 |
 |
Cognition TherapeuticsCGTX |
$0.98 0.3% | $93M | 48 |
 |
Aldeyra TherapeuticsALDX |
$1.34 8.2% | $90M | 61 |
 |
Oncolytics BiotechONCY |
$0.75 3.4% | $98M | 50 |
 |
Fortress BiotechFBIO |
$2.52 2.0% | $88M | 55 |
Explore Cardiff Oncology Data
Frequently Asked Questions: Cardiff Oncology (CRDF)
Cardiff Oncology has an AltIndex AI Score of 57/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
57/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Cardiff Oncology (CRDF) stock is $1.21 with a market cap of $94M.
As of today, Cardiff Oncology’s PE (Price to Earnings) ratio is —.
View the latest Cardiff Oncology insider transactions to see recent buying and selling activity by company executives and directors.
Check the Cardiff Oncology congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The CRDF stock price chart above shows Cardiff Oncology’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Cardiff Oncology technical analysis for RSI, moving averages, and more.
See the stocks similar to Cardiff Oncology section on this page for companies in the same industry ranked by market cap and AI Score.
